Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. WVE
WVE logo

WVE Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy WAVE Life Sciences Ltd (WVE) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
6.160
1 Day change
3.53%
52 Week Range
21.730
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Wave Life Sciences Ltd (WVE) is not a strong buy for a beginner, long-term investor at this time. While the stock has shown recent price momentum and has a positive MACD, the bearish moving averages and lack of significant catalysts or trading signals suggest limited immediate upside potential. Additionally, analyst sentiment is mixed with lowered price targets, and there are no recent influential trades or news to drive the stock higher.

Technical Analysis

The MACD histogram is positive at 0.0815 and expanding, indicating bullish momentum. RSI is neutral at 61.452, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near resistance levels (R1: 6.165, R2: 6.37), suggesting limited upward movement in the short term.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

The low put-call ratios indicate bullish sentiment among options traders, but the low implied volatility rank (16.62) suggests limited potential for significant price swings.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
6
Buy
5

Positive Catalysts

  • The MACD indicates positive momentum, and options data suggests a bullish sentiment. Analysts continue to see potential in the company's RNA editing technology, albeit with tempered expectations.

Neutral/Negative Catalysts

  • Bearish moving averages and mixed analyst sentiment with multiple price target reductions. Lack of recent news or significant trading activity from insiders, hedge funds, or influential figures. No recent congress trading data or financial performance updates.

Financial Performance

No financial data available for the latest quarter. Unable to assess growth trends or recent performance.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst sentiment is mixed. While most analysts maintain a Buy or Outperform rating, there have been significant reductions in price targets across the board, reflecting higher perceived risks and underwhelming data from recent clinical updates.

Wall Street analysts forecast WVE stock price to rise
14 Analyst Rating
Wall Street analysts forecast WVE stock price to rise
14 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.950
sliders
Low
21
Averages
33
High
50
Current: 5.950
sliders
Low
21
Averages
33
High
50
Wells Fargo
NULL
to
Overweight
maintain
$13 -> $14
AI Analysis
2026-05-20
Reason
Wells Fargo
Price Target
$13 -> $14
AI Analysis
2026-05-20
maintain
NULL
to
Overweight
Reason
Wells Fargo raised the firm's price target on Wave Life Sciences to $14 from $13 and keeps an Overweight rating on the shares. The firm notes the WVE-007 update included 600mg SAD data, which looked better than low/mid doses on M/Z-AAT and seems protective. However, the efficacy is lower than BEAM-302. Wells is moving probability of success up to 33%.
H.C. Wainwright
Buy
downgrade
$18 -> $13
2026-05-19
Reason
H.C. Wainwright
Price Target
$18 -> $13
2026-05-19
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Wave Life Sciences to $13 from $18 and keeps a Buy rating on the shares. WVE-006's readout at the American Thoracic Society Conference validated RNA editing as a modality but fell short with respect to the landscape, the analyst tells investors in a research note. The firm says Sanofi's concurrent Phase 2 data raise the commercial bar, and BEAM-302 retains a 12-18 month regulatory lead. H.C. Wainwright believes WVE-006 "delivered an underwhelming readout."
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for WVE
Unlock Now

People Also Watch